Chimeric Therapeutics Ltd begins collaboration with Sarah Cannon Research Institute for glioblastoma clinical trial
Chimeric Therapeutics Ltd (ASX:CHM), the only ASX clinical-stage cell therapy company, welcomes the participation of leading US centre Sarah Cannon Research...
United States Jason Litten Chimeric Therapeutics Ltd Sarah Cannon Research Institute American Society Of Clinical Oncology Sarah Cannon Transplant
Source: proactiveinvestors.com.au